Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
07 avr. 2020 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
27 févr. 2020 16h05 HE
|
Morphic Therapeutic
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel Disease
14 févr. 2020 11h29 HE
|
Morphic Therapeutic
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro and in vivo models ...
Metacrine to Present at Jefferies 2019 London Healthcare Conference
18 nov. 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures
18 sept. 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine Doses First Patient in 12-Week NASH Proof-of-Concept Trial with a Sustained FXR Agonist
09 juil. 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, July 09, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019
02 juil. 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present at Jefferies 2019 Global Healthcare Conference
21 mai 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019
13 mai 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
04 avr. 2019 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...